請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72675
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林?輝 | |
dc.contributor.author | Ming-Yen Hsiao | en |
dc.contributor.author | 蕭名彥 | zh_TW |
dc.date.accessioned | 2021-06-17T07:03:21Z | - |
dc.date.available | 2019-07-31 | |
dc.date.copyright | 2019-07-31 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-30 | |
dc.identifier.citation | [1] J. F. Kaux, B. Forthomme, C. L. Goff, J. M. Crielaard, and J. L. Croisier, 'Current opinions on tendinopathy,' J Sports Sci Med, vol. 10, no. 2, pp. 238-53, 2011.
[2] M. Reinking, 'Tendinopathy in athletes,' Physical therapy in sport : official journal of the Association of Chartered Physiotherapists in Sports Medicine, vol. 13, no. 1, pp. 3-10, Feb 2012. [3] P. Sharma and N. Maffulli, 'Biology of tendon injury: healing, modeling and remodeling,' Journal of musculoskeletal & neuronal interactions, vol. 6, no. 2, pp. 181-90, Apr-Jun 2006. [4] S. P. Arnoczky, M. Lavagnino, and M. Egerbacher, 'The mechanobiological aetiopathogenesis of tendinopathy: is it the over-stimulation or the under-stimulation of tendon cells?,' International journal of experimental pathology, vol. 88, no. 4, pp. 217-26, Aug 2007. [5] G. Riley, 'Tendinopathy--from basic science to treatment,' Nat Clin Pract Rheumatol, vol. 4, no. 2, pp. 82-9, Feb 2008. [6] A. D'Addona, N. Maffulli, S. Formisano, and D. Rosa, 'Inflammation in tendinopathy,' Surgeon, vol. 15, no. 5, pp. 297-302, Oct 2017. [7] P. Sharma and N. Maffulli, 'Tendon injury and tendinopathy: healing and repair,' The Journal of bone and joint surgery. American volume, vol. 87, no. 1, pp. 187-202, Jan 2005. [8] N. Andarawis-Puri, E. L. Flatow, and L. J. Soslowsky, 'Tendon basic science: Development, repair, regeneration, and healing,' Journal of orthopaedic research : official publication of the Orthopaedic Research Society, vol. 33, no. 6, pp. 780-4, Jun 2015. [9] M. Favata et al., 'Regenerative properties of fetal sheep tendon are not adversely affected by transplantation into an adult environment,' Journal of orthopaedic research : official publication of the Orthopaedic Research Society, vol. 24, no. 11, pp. 2124-32, Nov 2006. [10] M. Berglund, D. A. Hart, and M. Wiig, 'The inflammatory response and hyaluronan synthases in the rabbit flexor tendon and tendon sheath following injury,' The Journal of hand surgery, European volume, vol. 32, no. 5, pp. 581-7, Oct 2007. [11] F. Kaleagasioglu and E. Olcay, 'Fluoroquinolone-induced tendinopathy: etiology and preventive measures,' Tohoku J Exp Med, vol. 226, no. 4, pp. 251-8, 2012. [12] U. G. Longo, A. Berton, N. Papapietro, N. Maffulli, and V. Denaro, 'Epidemiology, genetics and biological factors of rotator cuff tears,' Med Sport Sci, vol. 57, pp. 1-9, 2012. [13] U. G. Longo, F. Oliva, V. Denaro, and N. Maffulli, 'Oxygen species and overuse tendinopathy in athletes,' Disability and rehabilitation, vol. 30, no. 20-22, pp. 1563-71, 2008. [14] H. Sies, 'Role of metabolic H2O2 generation: redox signaling and oxidative stress,' J Biol Chem, vol. 289, no. 13, pp. 8735-41, Mar 28 2014. [15] H. Zou, E. Stoppani, D. Volonte, and F. Galbiati, 'Caveolin-1, cellular senescence and age-related diseases,' Mech Ageing Dev, vol. 132, no. 11-12, pp. 533-42, Nov-Dec 2011. [16] P. P. Lui, L. S. Chan, Y. W. Lee, S. C. Fu, and K. M. Chan, 'Sustained expression of proteoglycans and collagen type III/type I ratio in a calcified tendinopathy model,' Rheumatology, vol. 49, no. 2, pp. 231-9, Feb 2010. [17] T. Samiric, J. Parkinson, M. Z. Ilic, J. Cook, J. A. Feller, and C. J. Handley, 'Changes in the composition of the extracellular matrix in patellar tendinopathy,' Matrix biology : journal of the International Society for Matrix Biology, vol. 28, no. 4, pp. 230-6, May 2009. [18] P. P. Lui, 'Histopathological changes in tendinopathy--potential roles of BMPs?,' Rheumatology, vol. 52, no. 12, pp. 2116-26, Dec 2013. [19] P. P. Lui, L. S. Chan, Y. C. Cheuk, Y. W. Lee, and K. M. Chan, 'Expression of bone morphogenetic protein-2 in the chondrogenic and ossifying sites of calcific tendinopathy and traumatic tendon injury rat models,' Journal of orthopaedic surgery and research, vol. 4, p. 27, 2009. [20] Y. F. Rui, P. P. Lui, C. G. Rolf, Y. M. Wong, Y. W. Lee, and K. M. Chan, 'Expression of chondro-osteogenic BMPs in clinical samples of patellar tendinopathy,' Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, vol. 20, no. 7, pp. 1409-17, Jul 2012. [21] K. Lipman, C. Wang, K. Ting, C. Soo, and Z. Zheng, 'Tendinopathy: injury, repair, and current exploration,' Drug Des Devel Ther, vol. 12, pp. 591-603, 2018. [22] I. Andia and N. Maffulli, 'A contemporary view of platelet-rich plasma therapies: moving toward refined clinical protocols and precise indications,' Regen Med, vol. 13, no. 6, pp. 717-728, Sep 2018. [23] I. Andia and N. Maffulli, 'How far have biological therapies come in regenerative sports medicine?,' (in English), Expert Opin Biol Th, vol. 18, no. 7, pp. 785-793, 2018. [24] Y. F. Rui, P. P. Lui, M. Ni, L. S. Chan, Y. W. Lee, and K. M. Chan, 'Mechanical loading increased BMP-2 expression which promoted osteogenic differentiation of tendon-derived stem cells,' Journal of orthopaedic research : official publication of the Orthopaedic Research Society, vol. 29, no. 3, pp. 390-6, Mar 2011. [25] Y. Shi et al., 'Uniaxial mechanical tension promoted osteogenic differentiation of rat tendon-derived stem cells (rTDSCs) via the Wnt5a-RhoA pathway,' Journal of cellular biochemistry, vol. 113, no. 10, pp. 3133-42, Oct 2012. [26] J. Zhang and J. H. Wang, 'Mechanobiological response of tendon stem cells: implications of tendon homeostasis and pathogenesis of tendinopathy,' Journal of orthopaedic research : official publication of the Orthopaedic Research Society, vol. 28, no. 5, pp. 639-43, May 2010. [27] Y. Li et al., 'Engineering cell alignment in vitro,' Biotechnology advances, vol. 32, no. 2, pp. 347-65, Mar-Apr 2014. [28] P. P. Lui and K. M. Chan, 'Tendon-derived stem cells (TDSCs): from basic science to potential roles in tendon pathology and tissue engineering applications,' Stem cell reviews, vol. 7, no. 4, pp. 883-97, Nov 2011. [29] M. Afzal, A. M. Safer, and M. Menon, 'Green tea polyphenols and their potential role in health and disease,' Inflammopharmacology, vol. 23, no. 4, pp. 151-61, Aug 2015. [30] H. S. Kim, M. J. Quon, and J. A. Kim, 'New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate,' Redox Biol, vol. 2, pp. 187-95, 2014. [31] S. A. Navarro, K. G. Serafim, S. S. Mizokami, M. S. Hohmann, R. Casagrande, and W. A. Verri, Jr., 'Analgesic activity of piracetam: effect on cytokine production and oxidative stress,' Pharmacol Biochem Behav, vol. 105, pp. 183-92, Apr 2013. [32] D. K. Verma, N. Joshi, K. S. Raju, M. Wahajuddin, R. K. Singh, and S. Singh, 'Metabolic enhancer piracetam attenuates rotenone induced oxidative stress: a study in different rat brain regions,' Acta Neurobiol Exp (Wars), vol. 75, no. 4, pp. 399-411, 2015. [33] B. Winblad, 'Piracetam: a review of pharmacological properties and clinical uses,' CNS Drug Rev, vol. 11, no. 2, pp. 169-82, Summer 2005. [34] M.-Y. Hsiao et al., 'The Effect of the Repression of Oxidative Stress on Tenocyte Differentiation: A Preliminary Study of a Rat Cell Model Using a Novel Differential Tensile Strain Bioreactor,' International Journal of Molecular Sciences, vol. 20, no. 14, 2019. [35] R. D. Price, M. G. Berry, and H. A. Navsaria, 'Hyaluronic acid: the scientific and clinical evidence,' J Plast Reconstr Aesthet Surg, vol. 60, no. 10, pp. 1110-9, 2007. [36] M. M. Reijnen, R. P. Bleichrodt, and H. van Goor, 'Pathophysiology of intra-abdominal adhesion and abscess formation, and the effect of hyaluronan,' Br J Surg, vol. 90, no. 5, pp. 533-41, May 2003. [37] R. D. Altman, A. Manjoo, A. Fierlinger, F. Niazi, and M. Nicholls, 'The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review,' BMC Musculoskelet Disord, vol. 16, p. 321, Oct 26 2015. [38] J. E. Rayahin, J. S. Buhrman, Y. Zhang, T. J. Koh, and R. A. Gemeinhart, 'High and low molecular weight hyaluronic acid differentially influence macrophage activation,' ACS Biomater Sci Eng, vol. 1, no. 7, pp. 481-493, Jul 13 2015. [39] M. Wobig et al., 'The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan,' Clin Ther, vol. 21, no. 9, pp. 1549-62, Sep 1999. [40] J. F. Kaux, A. Samson, and J. M. Crielaard, 'Hyaluronic acid and tendon lesions,' Muscles Ligaments Tendons J, vol. 5, no. 4, pp. 264-9, Oct-Dec 2015. [41] M. Yoshida, H. Funasaki, M. Kubota, and K. Marumo, 'Therapeutic effects of high molecular weight hyaluronan injections for tendinopathy in a rat model,' J Orthop Sci, vol. 20, no. 1, pp. 186-95, Jan 2015. [42] A. Frizziero et al., 'Hyaluronic acid injections protect patellar tendon from detraining-associated damage,' Histol Histopathol, vol. 30, no. 9, pp. 1079-88, Sep 2015. [43] W. Y. Su, Y. C. Chen, and F. H. Lin, 'Injectable oxidized hyaluronic acid/adipic acid dihydrazide hydrogel for nucleus pulposus regeneration,' Acta Biomater, vol. 6, no. 8, pp. 3044-55, Aug 2010. [44] N. O. Rasheed, L. A. Ahmed, D. M. Abdallah, and B. M. El-Sayeh, 'Nephro-toxic effects of intraperitoneally injected EGCG in diabetic mice: involvement of oxidative stress, inflammation and apoptosis,' Sci Rep, vol. 7, p. 40617, Jan 18 2017. [45] P. C. Lin, 'The preparation of hyaluronic acid-based hydrogel for control-release regimen in tendinosis treatment,' MS, National Taiwan University, Taipei, Taiwan, 2016. [46] F. H. Lin, M. Y. Hsiao, W. S. Chen, C. H. Hsu, P. C. Lin '差別週期形變牽拉之細胞培養系統,' R.O.C. Patent Appl. 106106300, 2017. [47] J. Chen et al., 'Autologous tenocyte therapy for experimental Achilles tendinopathy in a rabbit model,' Tissue Eng Part A, vol. 17, no. 15-16, pp. 2037-48, Aug 2011. [48] O. Krupkova et al., 'The Natural Polyphenol Epigallocatechin Gallate Protects Intervertebral Disc Cells from Oxidative Stress,' Oxid Med Cell Longev, vol. 2016, p. 7031397, 2016. [49] J. M. Chen, S. H. Lee, T. T. Tsai, C. C. Niu, L. H. Chen, and W. J. Chen, 'Anti-adhesive effect of hyaluronate in a rabbit laminectomy model,' Biomed J, vol. 37, no. 4, pp. 218-24, Jul-Aug 2014. [50] F. Salamanna et al., 'Metabolic and cytoprotective effects of in vivo peri-patellar hyaluronic acid injections in cultured tenocytes,' Connect Tissue Res, vol. 56, no. 1, pp. 35-43, Feb 2015. [51] S. Chaudhury and A. J. Carr, 'Lessons we can learn from gene expression patterns in rotator cuff tears and tendinopathies,' Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.], vol. 21, no. 2, pp. 191-9, Feb 2012. [52] P. P. Y. Lui, S. C. Fu, L. S. Chan, L. K. Hung, and K. M. Chan, 'Chondrocyte Phenotype and Ectopic Ossification in Collagenase-induced Tendon Degeneration,' (in English), J Histochem Cytochem, vol. 57, no. 2, pp. 91-100, Feb 2009. [53] M. Elsaadany, K. Winters, S. Adams, A. Stasuk, H. Ayan, and E. Yildirim-Ayan, 'Equiaxial Strain Modulates Adipose-derived Stem Cell Differentiation within 3D Biphasic Scaffolds towards Annulus Fibrosus,' Sci Rep, vol. 7, no. 1, p. 12868, Oct 9 2017. [54] D. H. Lee et al., 'Isolation and expansion of synovial CD34(-)CD44(+)CD90(+) mesenchymal stem cells: comparison of an enzymatic method and a direct explant technique,' Connect Tissue Res, vol. 52, no. 3, pp. 226-34, Jun 2011. [55] M. R. Oliveira, S. F. Nabavi, M. Daglia, L. Rastrelli, and S. M. Nabavi, 'Epigallocatechin gallate and mitochondria-A story of life and death,' Pharmacol Res, vol. 104, pp. 70-85, Feb 2016. [56] R. J. Kim, Y. S. Hah, J. R. Kang, and H. B. Park, 'Antioxidant's cytoprotective effects on rotator cuff tenofibroblasts exposed to aminoamide local anesthetics,' Journal of orthopaedic research : official publication of the Orthopaedic Research Society, vol. 33, no. 7, pp. 1001-7, Jul 2015. [57] Z. He et al., 'Piracetam ameliorated oxygen and glucose deprivation-induced injury in rat cortical neurons via inhibition of oxidative stress, excitatory amino acids release and P53/Bax,' Cell Mol Neurobiol, vol. 34, no. 4, pp. 539-47, May 2014. [58] E. Kalkan et al., 'Effects of iloprost and piracetam in spinal cord ischemia-reperfusion injury in the rabbit,' Spinal Cord, vol. 49, no. 1, pp. 81-6, Jan 2011. [59] S. Tuncer, S. Ayhan, K. Findikcioglu, H. Ergun, and I. Tuncer, 'Effect of systemic piracetam treatment on flap survival and vascular endothelial growth factor expression after ischemia-reperfusion injury,' J Reconstr Microsurg, vol. 27, no. 7, pp. 409-18, Sep 2011. [60] D. Tuglu et al., 'Protective effects of udenafil citrate, piracetam and dexmedetomidine treatment on testicular torsion/detorsion-induced ischaemia/reperfusion injury in rats,' Andrologia, vol. 48, no. 6, pp. 676-82, Aug 2016. [61] A. Sullo, N. Maffulli, G. Capasso, and V. Testa, 'The effects of prolonged peritendinous administration of PGE1 to the rat Achilles tendon: a possible animal model of chronic Achilles tendinopathy,' J Orthop Sci, vol. 6, no. 4, pp. 349-57, 2001. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72675 | - |
dc.description.abstract | 肌腱病變 ( Tendinopathy) 是臨床上最常見的退化性疾病之一,占了接近三分之一的肌肉骨骼系統疾患,常造成慢性疼痛,影響病患之日常生活功能及生活品質甚劇。一般認為造成肌腱病變成的病因為過度使用造成反覆微小創傷(accumulative microtraumas)、癒合不良(impaired healing)以及氧化壓力(oxidative stress)等。由於對其病理機轉未能完全了解,肌腱病變目前的處置上多以症狀控制、休息及活動調整為主,並無好的特異性根本治療;許多治療需要冗長的療程及重複注射,並且很少能真正改變疾病的惡化。
本研究以合成氧化透明質酸(hyaluronic acid, HA)與己二酸醯肼 ( Adipic dihydrazide, ADH)的交聯水膠(oxi-HA/ADH)作為本身對於肌腱病變即具有治療效用的藥物載體,並結合其他治療藥物,達到藥物緩釋的作用。目的是由疾病的病生理學進行特異性治療,同時減少氧化壓力及促進肌腱癒合過程,以早期阻斷肌腱病變的產生。 細胞實驗中,本研究創新設計一差別形變週期拉伸裝置(differential uniaxial tensile strain bioreactor),可以使用同一機具、在同一群培養細胞同時進行不同形變量的拉伸,以模擬細胞在正常生理及過度受力之病理狀態。本裝置將使實驗變因更嚴格控制。在大鼠肌腱病變細胞模型結果發現,具抗氧化作用的兒茶素 (epigallocatechin gallate, EGCG)以及細胞保護作用的藥物吡拉西坦 (piracetam)可以減少肌腱細胞在週期性高拉伸應力下的異常分化基因表現,顯示抑制氧化壓力可能是治療肌腱病變的有效方法之一。 以水膠做為兒茶素的藥物載體具有緩釋的藥物釋放特性。水膠本身在大鼠肌腱病變細胞模型(週期性高拉伸應力)及活體模型(膠原蛋白酶注射)都具有治療效果;水膠結合兒茶素後對於肌腱病變有更好的抑制效果,在活體模型中有效減少了膠原蛋白酶注射後造成的肌腱病變現象,如膠原蛋白結構散亂、細胞增生及血管新生等,也抑制了肌腱細胞的異常分化基因表現。 本研究結果指出,在肌腱病變的早期以不同藥物分別阻斷不同病生理路徑可能是未來治療肌腱病變的方向,特別是減少氧化壓力及促進癒合過程,提供了有效解決肌腱病變治療的可能策略。本研究建立的肌腱病變實驗模組及藥物載體未來將可應用於肌腱病變病生理學的基礎研究,以及開發潛在的疾病治療標的。 | zh_TW |
dc.description.abstract | Resulting from accumulative microtraumas, impaired healing and oxidative stress, tendinopathy is a debilitating and relentlessly deteriorating disease that greatly affects daily function and quality of life. Current therapy usually provides symptomatic relief only, partly because of incomplete understanding of the pathophysiology of the disease. Sufferers undergo repetitive and protracted treatment courses that rarely alter the disease process.
We developed a sustained-release regimen with an intrinsic therapeutic effect in tendinopathy treatment, using oxidised hyaluronic acid/adipic acid dihydrazide hydrogel (oxi-HA/ADH) as both the drug carrier and a mitigating agent of symptoms. By facilitating the healing process and mitigating oxidative stress, we attempt to halt tendinopathy early in the disease course. A novel bioreactor that can exert different ranges of cyclic uniaxial tensile strain on the cultured cells simultaneously was fabricated, which enables the simulation of both physiological and pathological (mechanical overloaded) status with otherwise identical experimental conditions. The results showed that the potent antioxidative (epigallocatechin gallate, EGCG) and the cytoprotecitve medication (piracetam) could diminish the expression of genes representing aberrant tenocyte differentiation in the rat cell model of tendinopathy induced by cyclic uniaxial stretching, indicating that eliminating oxidative stress could be a potential strategy in the treatment of tendinopathy. EGCG incorporated into oxi-HA/ADH showed sustained-release properties. Oxi-HA/ADH itself could mitigate tendinopathy changes both in vitro (cyclic stretching induced tendinopathy model) and in vivo (collagenase injection-induced tendinopathy model). In addition, EGCG-loaded oxi-HA/ADH conferred an additional protective effect in both models, including alleviating disorganisation of the collagen fibres, hypercellularity and hypervascularity, and decreasing the expression of genes representing aberrant tenocyte differentiation. The regimen opens a new window of tendinopathy treatment, in which the relentlessly degenerative process of tendinopathy is arrested at an early stage by inducing multiple pathways, including the healing process and oxidative stress mitigation. The established experimental model and drug carrier system provide a platform for exploring pathophysiology of tendinopathy as well as new therapeutics against this debilitating disease. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:03:21Z (GMT). No. of bitstreams: 1 ntu-108-F04548007-1.pdf: 3713039 bytes, checksum: 4b7d9ee4716f9162943336f3c1296728 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 誌謝 I
中文摘要 II ABSTRACT IV CONTENTS VI LIST OF FIGURES IX LIST OF TABLES XI LIST OF ABBREVIATION XII Chapter 1 Introduction 1 1.1 Unmet clinical needs 1 1.2 Pathophysiology of tendinopathy 2 1.3 Treatment of tendinopathy 4 1.4 Cell model of tendinopathy 6 1.5 Antioxidative and cytoprotective medications 6 1.6 Hyaluronic acid based hydrogel 11 1.7 The aims of this study 12 Chapter 2 Materials and Methods 14 2.1 Study protocols 14 2.1.1 In vitro model – cyclic uniaxial stretching 15 2.1.2 In vivo model- collagenase-induced tendinopathy 17 2.2 Differential uniaxial tensile strain bioreactor 19 2.3 Isolation and culture of TDCs 22 2.4 Characterization of TDCs 23 2.5 Quantitative PCR 24 2.6 Evaluation of oxi-HA/ADH as drug carrier 25 2.6.1 Preparation of oxi-HA/ADH 25 2.6.2 Cytocompatibility and cytotoxicity 27 2.6.3 Drug release profile 28 2.7 Histology 28 2.8 Statistical analysis 29 Chapter 3 Results 30 3.1 Differential uniaxial tensile strain bioreactor 30 3.2 Characteristics of TDCs 31 3.3 Cytocompatibility and cytotoxicity 33 3.4 Drug release profile 35 3.5 Effect of EGCG-loaded oxi-HA/ADH on TDCs 37 3.6 Effect of in vivo injection of EGCG-loaded oxi-HA/ADH 39 3.6.1 Histology 39 3.6.2 Gene expressions 42 Chapter 4 Discussion 44 4.1 Significance 44 4.2 Oxi-HA/ADH for tendinopathy treatment 45 4.3 Differential tensile strain bioreactor 46 4.4 Effect of cyclic uniaxial stretching on TDCs 46 4.5 Effect of EGCG and piracetam 48 4.6 Study limitations 49 Chapter 5 Conclusion 52 Chapter 6 Future Works 54 REFERENCES 55 APPENDIX A RESUME 63 APPENDIX B PUBLICATIONS 65 | |
dc.language.iso | en | |
dc.title | 以透明質酸水膠作為長效釋放藥物載體進行慢性肌腱病變治療 | zh_TW |
dc.title | The Preparation and Evaluation of Hyaluronate-Based Hydrogel as Sustained Release Drug Carrier for Tendinopathy | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 陳文翔 | |
dc.contributor.oralexamcommittee | 郭士民,陳博洲,許智欽 | |
dc.subject.keyword | 肌腱病變,透明質酸,水膠,緩釋,藥物載體,抗氧化, | zh_TW |
dc.subject.keyword | tendinopathy,hyaluronic acid,hydrogel,sustained-release,drug carrier,antioxidative, | en |
dc.relation.page | 72 | |
dc.identifier.doi | 10.6342/NTU201901791 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-30 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.63 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。